Agomelatine and its therapeutic potential in the depressed patient

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 4, 2007, Pages 423-428

  Kennedy, Sidney H ^a   Eisfeld, Beata S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Agomelatine; Antidepressant; Efficacy; Major depressive disorder; Tolerability

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; FLUOXETINE; LITHIUM; MELATONIN 2 RECEPTOR; MIRTAZAPINE; PAROXETINE; PLACEBO; SEROTONIN 2C RECEPTOR; VALPROIC ACID; VENLAFAXINE;

ABNORMAL LABORATORY RESULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CARDIOTOXICITY; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; NEPHROTOXICITY; NONHUMAN; ORGASM DISORDER; POLYSOMNOGRAPHY; SEDATION; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SLEEP DISORDER; SLEEP PATTERN; SLEEP WAKING CYCLE; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

EID: 35648932989     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, et al. 1993. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav, 46:45-9.
2. Audinot V, Mailliet F, Lahaye BC, et al. 2003. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol, 6:553-61.
3. Banasr M, Soumier A, Hery M, et al. 2006. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry, 59:1087-96.
4. Barden N, Shink E, Labbe M, et al. 2005. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry, 29:908-16.
5. Bertaina-Anglade V, Drieu la Rochelle C, Boyer PA, et al. 2006. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol, 17:703-13.
6. Bogaards JJ, Hissink EM, Briggs M, et al. 2000. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci, 12:117-24.
7. Boivin DB. 2000. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci, 25:446-58.
8. Bourin M, Mocaer E, Porsolt R. 2004. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci, 29:126-33.
9. Clayton AH, Pradko JF, Croft HA, et al. 2002. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry, 63:357-66.
10. den Boer JA, Bosker FJ, Meesters Y. 2006. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol, 21(Suppl 1):S21-4.
11. Dijk DJ, Cajochen C. 1997. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms, 12:627-35.
12. Dubocovich ML. 2006. Drug evaluation: Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs, 7:670-80.
13. Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol Psychiatry, 59:1116-27.
14. 2:B receptor profile in the rat central nervous system. Neuroscience, 76:323-9.
15. Fuchs E, Simon M, Schmelting B. 2006. Pharmacology of a new antide-pressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol, 21(Suppl 1):SI7-20.
16. Guelfi JD, Calabrese JR. 2005. Efficacy and safety of the new antidepressant agomelatine in combination with mood stabilizer in bipolar I patients with a major depressive episode. Bipolar Disord, 7(Suppl 2):63.
17. Guilleminault C. 2005. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur Neuropsychopharmacol, 15(Suppl 3):S419.
18. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol, 32:50-5.
19. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry, 23:56-62.
20. Hanoun N, Mocaer E, Boyer PA, et al. 2004. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology, 47:515-26.
21. Kennedy SH. 2005. Sexual function in remitted depressed patients following agomelatine and venlafaxine XR treatment. Eur Neuropsychpharmacol, 15(Suppl 3):S440.
22. Kennedy SH. 2006. Favourable sexual profile of agomelatine in depressed patients. Eur Neuropsychopharmacolo, 16(Suppl 4):S319.
23. Kennedy SH, Dickens SE, Eisfeld BS, et al. 1999. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord, 56:201-8.
24. Kennedy SH, Eisfeld BS, Dickens SE, et al. 2000. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry, 61:276-81.
25. Kennedy SH, Eisfeld BS, Meyer JH, et al. 2001. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol, 16:105-114.
26. Kennedy SH, Emsley R. 2006. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol, 16:93-100.
27. Kennedy SH, Fulton KA, Bagby RM, et al. 2006. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry, 51:234-42.
28. Kennedy SH, Guilleminault C. 2006. Antidepressant efficacy of agomelatine 25-50 mg versus venlafaxine 75-150 mg: two randomized, double-blind tudies. Eur Neuropsychopharmacol, 16(Suppl 4): S319-20.
29. Krauchi K, Wirz-Justice A. 2001. Circadian clues to sleep onset mechanisms. Neuropsychopharmacology, 25(5 Suppl):S92-6.
30. Leproult R, Van Onderbergen A, L'hermite-Baleriaux M, et al. 2005. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf), 63:298-304.
31. Loo H, Hale A, D'haenen H. 2002. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol, 17:239-47.
32. Lopes MS, Quera-Salva MA, Guilleminault C. 2005. Cyclic Alternating Pattern in the NREM sleep of patients within major depression disorder: Baseline results and change over time with a new antidepressant: Agomelatine. Sleep Med, 6(Suppl 2):87-8.
33. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. 1996. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol, 11 (Suppl 4):41-6.
34. Malberg JE, Schechter LE. 2005. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des, 11:145-55.
35. Martinet L, Guardiola-Lemaitre B, Mocaer E. 1996. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav, 54:713-8.
36. McGahuey CA, Gelenberg AJ, Laukes CA, et al. 2000. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther, 26:25-40.
37. Millan MJ. 2004. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol, 500:371-84.
38. Millan MJ, Gobert A, Lejeune F, et al. 2003. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther, 306:954-64.
39. Millan MJ, Brocco M, Gobert A, et al. 2005. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic, and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl), 177:448-58.
40. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry, 134:3 82-9.
41. Montgomery SA, Baldwin DS, Riley A. 2002. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord, 69:119-40.
42. Montgomery SA, Kennedy SH, Burrows GD, et al. 2004. Absence of discontinuation symptoms with agomelatine and occurrence of dis-continuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol, 19:271-80.
43. Papp M, Gruca P, Boyer PA, et al. 2003. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology, 28:694-703.
44. Papp M, Litwa E, Gruca P, et al. 2006. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol, 17:9-18.
45. Parrott AC, Hindmarch I. 1978. Factor analysis of a sleep evaluation questionnaire. Psychol Med, 8:325-9.
46. Pineyro G, Blier P. 1999. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev, 51:533-91.
47. Quera-Salva MA, Vanier B, Chapotot F, et al. 2005. Effects of agomelatine on the sleep EEG in patients with major depressive disorder. J Eur Coll Neuropsychopharmacol, 15(Suppl 3):S435.
48. Radhakishun FS, van den Bos J, van der Heijden BC, et al. 2000. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol, 20:531-7.
49. Redman JR, Guardiola-Lemaitre B, Brown M, et al. 1995. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl), 118:385-90.
50. Rosenbaum JF, Fava M, Hoog SL, et al. 1998. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry, 44:77-87.
51. Rouillon F. 2006. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol, 21(Suppl 1):S31-5.
52. Simon M, Schmelting B, Molzër E, et al. 2004. Agomelatine restores sleep EEG activity in chronically stressed tree shrews. Program no 354.10. Abstract viewer Itinerary Planner. Society for Neurosciences, San Diego.
53. Smith D, Dempster C, Glanville J, et al. 2002. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry, 180:396-404.
54. Thase ME, Entsuah AR, Rudolph RL. 2001. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry, 178:234-41.
55. Trivedi MH, Rush AJ, Wisniewski SR, et al. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR°D: implications for clinical practice. Am J Psychiatry, 163:28-40.
56. Tuma J, Strubbe JH, Mocaer E, et al. 2005. Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol, 15:545-55.
57. Vacher R, Labbe M, Barden N, et al. 2002. Antidepressant action of S-20098 (agomelatine) in a transgenic mouse model. Int J Neuropsychopharmacol, 5(Suppl 1), S64.
58. van Rossum EF, Binder EB, Majer M, et al. 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry, 59:681-8.
59. Vanderkooy JD, Kennedy SH, Bagby RM. 2002. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry, 47:174-80.
60. Wilson S, Argyropoulos S. 2005. Antidepressants and sleep: a qualitative review of the literature. Drugs, 65:927-47.